NeuroOne Medical Technologies Corporation
corporate_fare Company Profile
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for NMTC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for NMTC spans 10-Q, 8-K, 424B5, 10-Q/A.
Recent high-impact activity:
- NeuroOne Posts 38% Q4 Revenue Growth, Lands Record $4.5M Order
- NeuroOne's StereoCED Platform Hits Key Milestone in Robotic Drug Delivery
- NeuroOne Q3: Revenue Up 16%, But Cash Drops to $2.0M and Going Concern Doubt Persists
- NeuroOne Q3 Revenue Up 16% to $2.0M, Gross Margin Hits 59.9%; Cash Drops to $2.0M
- NeuroOne Secures ISO 13485 Certification, Unlocking International Revenue Path
Financial Snapshot
Short Interest & Short Volume
2.39 days to coverFINRA reported short interest of 207,063 shares in NMTC as of the October 30, 2026 settlement, a 0.1% decrease from the prior period — about 2.4 days to cover at its recent average daily volume. On November 19, 2026, 29.6% of NMTC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for NMTC, detected from its recent SEC filings · based on capital-structure filings through 2026-06-12.
Increased ATM Capacity · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →